{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-302473","form_type":"8-K","ticker":"SPRO","cik":"0001701108","company_name":"Spero Therapeutics, Inc.","filed_at":"2026-07-14T10:30:09+00:00","discovered_at":"2026-07-14T10:35:01.396504+00:00","generated_at":"2026-07-14T10:35:11.187336+00:00","sec_items":["1.01","2.03","7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Spero in-licenses SP001 anti-CD40L antibody from Innovent, secures $105M non-dilutive financing","bullets":["In-licensed SP001 (anti-CD40L) from Innovent; Spero gets ex-China rights. Upfront $35M, milestones up to ~$1.05B, tiered royalties high single to mid-teen %.","SP001 Phase 2-ready; Spero plans Phase 2 in IgG4-RD in Q2 2027. Innovent plans Phase 2 in SjD in China by early 2027.","Secured $105M non-recourse notes from HCRx (KKR) at 10% interest, 9-year maturity, backed by Utebzi milestones/royalties from GSK.","Cash runway extended into H2 2029; proceeds to fund SP001 development.","Spero retains 35% of GSK proceeds after note repayment; HCRx gets 65% after note repayment."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-302473","json":"https://secwatch.observer/filing/0001193125-26-302473.json","markdown":"https://secwatch.observer/filing/0001193125-26-302473.md","text":"https://secwatch.observer/filing/0001193125-26-302473.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1701108/000119312526302473/0001193125-26-302473-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1701108/000119312526302473/d320658d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-07-14T10:35:11.187336+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}